<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72588">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02160717</url>
  </required_header>
  <id_info>
    <org_study_id>CCHMC-906</org_study_id>
    <secondary_id>UL1TR000077</secondary_id>
    <nct_id>NCT02160717</nct_id>
  </id_info>
  <brief_title>Risk of Diabetes in Young Turner Syndrome Patients</brief_title>
  <official_title>Beta-Cell Function in Young Turner Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Turner Syndrome is a common genetic disorder. Seventy percent of adults with Turner Syndrome
      have abnormalities in glucose metabolism which can lead to diabetes. The current screening
      guidelines for diabetes in Turner Syndrome are not specific and involve a fasting blood
      sugar once a year. The objective of this study is to determine if there are abnormalities in
      glucose metabolism and pancreatic function in young girls with Turner Syndrome. The study
      hypothesis is that pancreatic dysfunction (specifically of the beta cells that make insulin)
      is more prevalent in girls with Turner Syndrome compared to healthy controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted at Children's Hospital Medical Center, Cincinnati. The study
      will require 1 visit to the hospital where the subject will have an oral glucose tolerance
      test and a physical exam
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Beta-Cell Function measured as Disposition Index</measure>
    <time_frame>1 day at screening</time_frame>
    <description>Disposition index will be calculated based on the results of the oral glucose tolerance test using minimal modeling (computer program)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Turner Syndrome</condition>
  <arm_group>
    <arm_group_label>Turner Syndrome</arm_group_label>
    <description>Female with Turner Syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Healthy Female</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinic Turner Syndrome Center of Cincinnati Community Sample
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Turner Syndrome Females:

        Inclusion Criteria:

          -  Turner Syndrome confirmed by chromosomal testing

          -  On standard therapy (growth hormone and or estrogen)

        Exclusion Criteria:

          -  Type 1 or Type 2 diabetes

          -  Polycystic Ovarian Syndrome

          -  Pregnancy

          -  On any medications that alter blood sugar

        Healthy Female Controls:

        Inclusion Criteria:

          -  Healthy

        Exclusion Criteria:

          -  Type 1 or Type 2 diabetes

          -  Polycystic Ovarian Syndrome

          -  Pregnancy

          -  On any medications that alter blood sugar
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Backeljauw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Sheanon, MD</last_name>
    <phone>513-636-4549</phone>
    <email>Nicole.Sheanon@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe Backeljauw, MD</last_name>
    <phone>513-636-2759</phone>
    <email>Philippe.Backeljauw@cchmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Medical Center, Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Sheanon, MD</last_name>
      <phone>513-636-4549</phone>
      <email>Nicole.Sheanon@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Philippe Backeljauw, MD</last_name>
      <phone>513-636-2759</phone>
      <email>Philippe.Backeljauw@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe Backeljauw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Sheanon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deborah Elder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iris Gutmark-Little, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 25, 2015</lastchanged_date>
  <firstreceived_date>June 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Turner Syndrome</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Turner Syndrome</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
